TheStreet expects GTx Inc. (Nasdaq: GTX) to report disappointing results from two Phase III studies of its muscle wasting drug enobosarm sending the stock price tumbling $1.75 to close at $5.20.
GTx Expected To Disappoint
July 10, 2013 at 19:11 PM EDT
